About Inhibitor of growth protein 1
Inhibitor of growth protein 1 (ING1) is a protein
from Homo sapiens identified by UniProt accession
Q9UK53, 422 residues long.
MolForge cross-references it against 0 known binders and
92 disease associations.
Target properties
| Protein name | Inhibitor of growth protein 1 |
| UniProt accession | Q9UK53 |
| Gene | ING1 |
| Organism | Homo sapiens |
| Length | 422 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (92)
Diseases linked to this target (Open Targets).
- head and neck squamous cell carcinoma · score 0.55
- endometrial cancer · score 0.33
- neurodegenerative disease · score 0.26
- C-reactive protein measurement · score 0.18
- serum gamma-glutamyl transferase measurement · score 0.16
- coronary artery disease · score 0.09
- neoplasm · score 0.08
- oral squamous cell carcinoma · score 0.08
- aspartate aminotransferase measurement · score 0.07
- hepatocellular carcinoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UK53-F1 | alphafold | PREDICTED | 57.55 | — |
Amino-acid sequence (422 residues)
MSFVECPYHS PAERLVAEAD EGGPSAITGM GLCFRCLLFS FSGRSGVEGG RVDLNVFGSL GLQPWIGSSR CWGGPCSSAL RCGWFSSWPP PSKSAIPIGG GSRGAGRVSR WPPPHWLEAW RVSPLPLSPL SPATFGRGFI AVAVIPGLWA RGRGCSSDRL PRPAGPARRQ FQAASLLTRG WGRAWPWKQI LKELDECYER FSRETDGAQK RRMLHCVQRA LIRSQELGDE KIQIVSQMVE LVENRTRQVD SHVELFEAQQ ELGDTAGNSG KAGADRPKGE AAAQADKPNS KRSRRQRNNE NRENASSNHD HDDGASGTPK EKKAKTSKKK KRSKAKAERE ASPADLPIDP NEPTYCLCNQ VSYGEMIGCD NDECPIEWFH FSCVGLNHKP KGKWYCPKCR GENEKTMDKA LEKSKKERAY NR
Explore Inhibitor of growth protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets